Disclosure of Unlabeled Use and Investigational Product
Expiration Date: August 3, 2024
This session, which was included as part of the 2023 Ophthalmology 360 Summit Series, will provide an overview of dry eye disease (DED), including its quality-of-life impact, risk factors, and strategies for making a timely diagnosis, including how to distinguish between aqueous-deficient, hyperevaporative, and mixed-type DED. It will also review current treatment approaches, from topical agents to devices and procedures. The activity will include 2 patient case scenarios to demonstrate the real-world application of diagnostic and treatment approaches.
This activity is designed for an audience of ophthalmologists, optometrists, and other members of the healthcare team who treat patients with various eye conditions.
Upon completion of the educational activity, participants should be able to:
To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your certificate. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at
ketrea@akhcme.com
CE credit provided by AKH Inc., Advancing Knowledge in Healthcare
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 1.00
AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AKH Inc., Advancing Knowledge in Healthcare designates this asynchronous activity for a maximum of 1.0 COPE credit hours. Optometrists should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by independent educational grants from Alcon, Genentech, Regenxbio, Tarsus, Théa, and Visus.
Name
Relationship
Commercial Interest
Session Faculty
Eric Donnenfeld, MD (moderator)
Consultant, Ownership
Aeon
Consultant
Allegro
Consultant
Allergan
Consultant
Alcon
Consultant, Ownership
Aurion
Consultant
Avellino Labs
Ownership
Avedro
Consultant
Bausch + Lomb
Consultant, Ownership
CorneaGen
Consultant, Ownership
Covalent
Consultant
CRST
Consultant, Ownership
Crystilex
Consultant
BVI
Consultant
Blephex
Consultant
Dompe
Consultant, Ownership
ELT Sight
Consultant, Ownership
EyePoint Pharma
Consultant
Foresight
Consultant, Ownership
Glaukos
Consultant, Ownership
Ivantis
Consultant
Johnson & Johnson
Consultant
Kala
Consultant
Katena
Consultant, Ownership
Lacripen
Consultant, Ownership
LayerBio
Consultant, Ownership
LensGen
Consultant, Ownership
Mati Pharmaceuticals
Consultant, Ownership
Melt Pharmaceuticals
Consultant, Ownership
MDBackline
Consultant
Merck
Consultant, Ownership
Mimetogen
Consultant, Ownership
MOA
Consultant
Nanowafer
Consultant, Ownership
Novabay
Consultant
Novartis
Consultant
Novaliq
Ownership
Ocuhub
Consultant, Ownership
Ocular Innovations
Consultant, Ownership
Oculis
Consultant
Odyssey
Consultant
Omega Ophthalmics
Consultant
Oyster PointTherapeutics
Consultant
Pfizer
Consultant, Ownership
Pogotec
Consultant
Ocuhub
Consultant
Omeros
Ownership
Orasis
Consultant
PRN
Consultant, Ownership
Rayner
Consultant, Ownership
ReTear
Consultant, Ownership
RPS
Consultant
Shire
Consultant, Ownership
Strathspey Crown
Consultant
SUN
Consultant, Ownership
Surface
Consultant, Ownership
Tarsus
Consultant, Ownership
Tearlab
Consultant
Tearscience
Consultant
Thea
Consultant, Ownership
Veracity
Consultant, Ownership
Versant Ventures
Consultant, Ownership
Visionary Ventures
Consultant, Ownership
Visus
Consultant
Zeiss
Marjan Farid, MD (faculty)
Advisor, Consultant
Alcon
Advisor, Consultant
Alderya Therapeutics
Advisor, Consultant
Allergan
Advisor, Consultant
Bausch + Lomb
Advisor, Consultant
Bio-Tissue
Advisor, Consultant
Carl Zeiss Meditec
Advisor, Consultant
CorneaGen
Advisor, Consultant
Johnson & Johnson Vision
Advisor, Consultant
Novartis, Alcon Pharmaceuticals
Advisor, Consultant
Orasis Pharmaceuticals Inc
Advisor, Consultant
Oyster Point Pharma
Advisor, Consultant
Sun Ophthalmics
Advisor, Consultant
Tarsus
Advisor, Consultant, Stock
Kala Pharmaceuticals
Elise Kramer, OD, FAAO, FSLS, FBCLA (faculty)
Advisor, Consultant
Allergan
Advisor, Consultant, Speaker
Avellino
Advisor, Consultant, Speaker
Contamac
Advisor, Consultant, Speaker
Dompe
Advisor, Consultant
Euclid
Advisor, Consultant
Ocuphire
Advisor, Consultant
Orasis
Advisor, Consultant
Oyster Pointe Pharmaceuticals
Advisor, Consultant, Speaker
RegenerEyes
Advisor, Consultant, Speaker
RVL
Advisor, Consultant
Tarsus
Advisor, Consultant, Speaker
Visionary Optics
Dorothy Caputo, MA, BSN, RN, VP, Healthcare Continuing Education & Operations
N/A
Nothing to disclose
Michele Bielarski, RN (planner/reviewer)
N/A
Nothing to disclose
AKH Inc. Staff and Planners
N/A
Nothing to disclose
International Healthcare Media, LLC Staff and Planners
N/A
Nothing to disclose
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content.
Uncovering Dry Eye Disease in Clinical Practice: How Would You Diagnose and Treat?
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.